NYSE:ATNM Stock Quote
Actinium Pharmaceuticals Inc is a biotechnology company that focuses on the development of innovative therapies for cancer treatment
The company's primary emphasis is on harnessing the power of targeted radiotherapy, utilizing its proprietary platform to create treatments that deliver radiation directly to cancer cells while minimizing damage to surrounding healthy tissue. By advancing its pipeline of both therapeutic and diagnostic candidates, Actinium aims to improve patient outcomes in hematologic cancers and solid tumors, contributing to the overall evolution of cancer care. The company's efforts are geared towards addressing unmet medical needs in oncology and enhancing the effectiveness of existing treatment modalities.
Frequently Asked Questions
Are there any upcoming events or announcements from Actinium?
Actinium Pharmaceuticals regularly participates in industry conferences and events to share updates on its clinical trial progress and business developments. Investors and interested parties can stay informed about upcoming announcements by monitoring the company's official website and following their press releases.
How does Actinium approach partnerships and collaborations?
Actinium actively seeks partnerships and collaborations with academic institutions, healthcare organizations, and pharmaceutical companies to enhance its development capabilities and expand its research efforts. These collaborations aim to accelerate clinical trials, pool resources, and leverage complementary expertise.
How does Actinium ensure patient safety during clinical trials?
Actinium prioritizes patient safety during clinical trials by adhering to rigorous regulatory standards and ethical guidelines. This includes comprehensive informed consent processes, continuous monitoring of patient health, and stringent protocols for data collection and reporting adverse events to ensure the highest safety standards are maintained.
How does Actinium execute its drug development strategy?
Actinium executes its drug development strategy by leveraging its proprietary platforms for targeted alpha-particle radiation and conducting rigorous clinical trials to validate its therapeutic approaches. The company also aims to collaborate with leading academic and clinical institutions to enhance research outcomes and accelerate the development process.
How does Actinium handle intellectual property?
Actinium Pharmaceuticals actively manages its intellectual property by securing patents and proprietary rights for its technologies and product candidates. This strategy is crucial for protecting their innovations and ensuring a competitive edge in the biopharmaceutical industry, allowing the company to maintain exclusive rights to its breakthroughs.
Is Actinium Pharmaceuticals publicly traded?
Yes, Actinium Pharmaceuticals, Inc. is publicly traded on the New York Stock Exchange under the ticker symbol ATNM. Being publicly listed allows the company to raise capital for its research and development initiatives while providing transparency to investors.
What are some of Actinium's key product candidates?
Actinium Pharmaceuticals has several key product candidates in various stages of development, including Actimab-A, which is under investigation for the treatment of acute myeloid leukemia (AML), and Iomab-B, aimed at preparing patients for bone marrow transplant in advanced hematologic malignancies. Additionally, the company is exploring other applications for its radioimmunotherapy platform.
What are the company's future goals?
Actinium Pharmaceuticals aims to advance its product candidates through clinical trials, with the ultimate goal of obtaining regulatory approval and bringing innovative cancer therapies to market. Additionally, the company seeks to expand its pipeline through collaborations and partnerships to address a broader range of cancers.
What competitive advantages does Actinium have in the biopharmaceutical market?
Actinium holds several competitive advantages, including its proprietary technology for targeted alpha-particle therapy, experienced leadership, a focused pipeline addressing significant unmet medical needs, and a growing body of clinical data supporting the safety and efficacy of its treatments. These factors position Actinium favorably in the competitive biopharmaceutical landscape.
What does Actinium Pharmaceuticals, Inc. do?
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies to treat cancer. The company specializes in the field of targeted alpha-particle radiation, aiming to utilize its proprietary platforms to develop targeted therapies that can deliver radioisotopes directly to cancer cells, minimizing damage to surrounding healthy tissues.
What is the potential market for Actinium's therapies?
The potential market for Actinium's therapies is substantial, particularly given the increasing prevalence of cancer and the demand for innovative treatment options. With advancements in personalized medicine and targeted therapies, Actinium's unique approach to alpha-particle radioimmunotherapy positions it well within the growing biopharmaceutical market.
What is the primary focus of Actinium's research?
The primary focus of Actinium's research is on developing therapies that employ alpha-particle radioimmunotherapy, a method that targets cancerous cells for destruction while sparing normal cells. Their lead product candidates are designed to address unmet medical needs in hematologic malignancies and solid tumors by leveraging the selective targeting ability of antibodies combined with the potency of alpha radiation.
What is the significance of alpha-particle radiation in cancer treatment?
Alpha-particle radiation is significant in cancer treatment due to its high energy and short range, which allows for the precise targeting of malignant cells. This form of therapy can effectively destroy cancerous tissues with minimal impact on surrounding healthy cells, thereby reducing side effects and improving patient outcomes.
What milestones has Actinium achieved recently?
Recent milestones achieved by Actinium include successful completion of key clinical trial phases for its product candidates, the submission of applications to regulatory authorities, and collaborations with manufacturing partners that enhance its production capacity for clinical and commercial supply.
What type of clinical trials is Actinium currently conducting?
Actinium is conducting multiple clinical trials to evaluate the safety and efficacy of its lead product candidates. These trials include Phase 1 and Phase 2 studies, primarily focused on hematologic malignancies such as acute myeloid leukemia (AML) and the preparation of patients for stem cell transplants, examining various dosing regimens and combinations with other therapies.
What types of cancers does Actinium's therapies target?
Actinium's therapies primarily target hematologic malignancies, including acute myeloid leukemia (AML) and lymphomas. The company is also exploring potential applications in solid tumors, aiming to develop treatments that address high unmet medical needs across various cancer types.
Where can investors find financial information about Actinium?
Investors can find financial information about Actinium Pharmaceuticals through its investor relations section on the company's official website, which includes access to earnings reports, SEC filings, stock performance updates, and information on upcoming earnings calls and investor presentations.
Where is Actinium Pharmaceuticals, Inc. headquartered?
Actinium Pharmaceuticals, Inc. is headquartered in New York City, New York. This location situates the company in a vibrant biotech hub, allowing access to resources, talent, and partnerships crucial for advancing its innovative therapies.
Who are the key members of Actinium's leadership team?
The leadership team at Actinium Pharmaceuticals includes experienced professionals from diverse backgrounds in the biopharmaceutical industry. Key members include professionals with expertise in clinical development, regulatory affairs, finance, and business development, contributing to the strategic direction and growth of the company.
What is the current price of Actinium Pharmaceuticals, Inc. (Delaware) Common Stock?
The current price of Actinium Pharmaceuticals, Inc. (Delaware) Common Stock is 1.530
When was Actinium Pharmaceuticals, Inc. (Delaware) Common Stock last traded?
The last trade of Actinium Pharmaceuticals, Inc. (Delaware) Common Stock was at 3:51 pm EDT on April 2nd, 2025
What is the market capitalization of Actinium Pharmaceuticals, Inc. (Delaware) Common Stock?
The market capitalization of Actinium Pharmaceuticals, Inc. (Delaware) Common Stock is 32.64M
How many shares of Actinium Pharmaceuticals, Inc. (Delaware) Common Stock are outstanding?
Actinium Pharmaceuticals, Inc. (Delaware) Common Stock has 21.33M shares outstanding.